| Target Price | ¥3,009.00 |
| Price | ¥1,789.00 |
| Potential |
68.19%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Fuji Pharma Co.,ltd. 2027 .
The average Fuji Pharma Co.,ltd. target price is ¥3,009.00.
This is
68.19%
register free of charge
¥3,780.00
111.29%
register free of charge
¥2,323.00
29.85%
register free of charge
|
|
| A rating was issued by 6 analysts: 4 Analysts recommend Fuji Pharma Co.,ltd. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fuji Pharma Co.,ltd. stock has an average upside potential 2027 of
68.19%
register free of charge
|
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 51.68 | 60.95 |
| 12.01% | 17.94% | |
| EBITDA Margin | 12.50% | 17.32% |
| 10.72% | 38.51% | |
| Net Margin | 5.81% | 3.27% |
| 56.42% | 43.67% |
3 Analysts have issued a sales forecast Fuji Pharma Co.,ltd. 2026 . The average Fuji Pharma Co.,ltd. sales estimate is
This results in the following potential growth metrics:
3 Fuji Pharma Co.,ltd. Analysts have issued a net profit forecast 2026. The average Fuji Pharma Co.,ltd. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 122.93 | 76.41 |
| 51.37% | 37.84% | |
| P/E | 23.10 | |
| EV/Sales | 1.08 |
3 Analysts have issued a Fuji Pharma Co.,ltd. forecast for earnings per share. The average Fuji Pharma Co.,ltd. EPS is
This results in the following potential growth metrics and future valuations:
Fuji Pharma Co.,ltd....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


